The Korean Journal of Pain

The Korean Pain Society (대한통증학회)
권호 표지
DOI QR코드

DOI QR Code

Painful Boney Metastases

  • Smith, Howard S. (Department of Anesthesiology, Albany Medical College) ;
  • Mohsin, Intikhab (Department of Anesthesiology, Albany Medical College)
  • Received : 2013.05.29
  • Accepted : 2013.06.14
  • Published : 2013.07.01
Download PDF
⟨ Previous Next ⟩

Abstract

Boney metastasis may lead to terrible suffering from debilitating pain. The most likely malignancies that spread to bone are prostate, breast, and lung. Painful osseous metastases are typically associated with multiple episodes of breakthrough pain which may occur with activities of daily living, weight bearing, lifting, coughing, and sneezing. Almost half of these breakthrough pain episodes are rapid in onset and short in duration and 44% of episodes are unpredictable. Treatment strategies include: analgesic approaches with "triple opioid therapy", bisphosphonates, chemotherapeutic agents, hormonal therapy, interventional and surgical approaches, steroids, radiation (external beam radiation, radiopharmaceuticals), ablative techniques (radiofrequency ablation, cryoablation), and intrathecal analgesics.

Keywords

References

  1. Boyle P, Levin B; International Agency for Research on Cancer; World Health Organization. World cancer report 2008. Lyon, International Agency for Research on Cancer. 2008.
  2. Berruti A, Dogliotti L, Bitossi R, Fasolis G, Gorzegno G, Bellina M, et al. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J Urol 2000; 164: 1248-53. https://doi.org/10.1016/S0022-5347(05)67149-2
  3. Meuser T, Pietruck C, Radbruch L, Stute P, Lehmann KA, Grond S. Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain 2001; 93: 247-57. https://doi.org/10.1016/S0304-3959(01)00324-4
  4. van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 2007; 18: 1437-49. https://doi.org/10.1093/annonc/mdm056
  5. van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. High prevalence of pain in patients with cancer in a large population-based study in The Netherlands. Pain 2007; 132: 312-20. https://doi.org/10.1016/j.pain.2007.08.022
  6. Laird BJ, Walley J, Murray GD, Clausen E, Colvin LA, Fallon MT. Characterization of cancer-induced bone pain: an exploratory study. Support Care Cancer 2011; 19: 1393-401. https://doi.org/10.1007/s00520-010-0961-3
  7. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997; 69: 1-18. https://doi.org/10.1016/S0304-3959(96)03267-8
  8. Delaney A, Fleetwood-Walker SM, Colvin LA, Fallon M. Translational medicine: cancer pain mechanisms and management. Br J Anaesth 2008; 101: 87-94. https://doi.org/10.1093/bja/aen100
  9. Saftig P, Hunziker E, Wehmeyer O, Jones S, Boyde A, Rommerskirch W, et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci U S A 1998; 95: 13453-8. https://doi.org/10.1073/pnas.95.23.13453
  10. Everts V, Delaissé JM, Korper W, Jansen DC, Tigchelaar- Gutter W, Saftig P, et al. The bone lining cell: its role in cleaning Howship's lacunae and initiating bone formation. J Bone Miner Res 2002; 17: 77-90. https://doi.org/10.1359/jbmr.2002.17.1.77
  11. Sly WS, Hewett-Emmett D, Whyte MP, Yu YS, Tashian RE. Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. Proc Natl Acad Sci U S A 1983; 80: 2752-6. https://doi.org/10.1073/pnas.80.9.2752
  12. Josephsen K, Praetorius J, Frische S, Gawenis LR, Kwon TH, Agre P, et al. Targeted disruption of the Cl-/HCO3- exchanger Ae2 results in osteopetrosis in mice. Proc Natl Acad Sci U S A 2009; 106: 1638-41. https://doi.org/10.1073/pnas.0811682106
  13. Frattini A, Orchard PJ, Sobacchi C, Giliani S, Abinun M, Mattsson JP, et al. Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis. Nat Genet 2000; 25: 343-6. https://doi.org/10.1038/77131
  14. Karsdal MA, Henriksen K, Sørensen MG, Gram J, Schaller S, Dziegiel MH, et al. Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption. Am J Pathol 2005; 166: 467-76. https://doi.org/10.1016/S0002-9440(10)62269-9
  15. Baron R, Neff L, Louvard D, Courtoy PJ. Cell-mediated extracellular acidification and bone resorption: evidence for a low pH in resorbing lacunae and localization of a 100-kD lysosomal membrane protein at the osteoclast ruffled border. J Cell Biol 1985; 101: 2210-22. https://doi.org/10.1083/jcb.101.6.2210
  16. Miyazaki T, Tanaka S, Sanjay A, Baron R. The role of c-Src kinase in the regulation of osteoclast function. Mod Rheumatol 2006; 16: 68-74. https://doi.org/10.3109/s10165-006-0460-z
  17. Bradt J, Dileo C, Grocke D, Magill L. Music interventions for improving psychological and physical outcomes in cancer patients. Cochrane Database Syst Rev 2011; (8): CD006911.
  18. Jane SW, Chen SL, Wilkie DJ, Lin YC, Foreman SW, Beaton RD, et al. Effects of massage on pain, mood status, relaxation, and sleep in Taiwanese patients with metastatic bone pain: a randomized clinical trial. Pain 2011; 152: 2432-42. https://doi.org/10.1016/j.pain.2011.06.021
  19. Burton AW, Cleeland CS. Cancer pain: progress since the WHO guidelines. Pain Pract 2001; 1: 236-42. https://doi.org/10.1046/j.1533-2500.2001.01025.x
  20. Zech DF, Grond S, Lynch J, Hertel D, Lehmann KA. Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. Pain 1995; 63: 65-76. https://doi.org/10.1016/0304-3959(95)00017-M
  21. Mercadante S. Intravenous morphine for management of cancer pain. Lancet Oncol 2010; 11: 484-9. https://doi.org/10.1016/S1470-2045(09)70350-X
  22. Vielhaber A, Portenoy RK. Advances in cancer pain management. Hematol Oncol Clin North Am 2002; 16: 527-41. https://doi.org/10.1016/S0889-8588(02)00016-3
  23. Urch C. The pathophysiology of cancer-induced bone pain: current understanding. Palliat Med 2004; 18: 267-74. https://doi.org/10.1191/0269216304pm887ra
  24. Eisenberg E, Berkey CS, Carr DB, Mosteller F, Chalmers TC. Efficacy and safety of nonsteroidal antiinflammatory drugs for cancer pain: a meta-analysis. J Clin Oncol 1994; 12: 2756-65. https://doi.org/10.1200/JCO.1994.12.12.2756
  25. Levick S, Jacobs C, Loukas DF, Gordon DH, Meyskens FL, Uhm K. Naproxen sodium in treatment of bone pain due to metastatic cancer. Pain 1988; 35: 253-8. https://doi.org/10.1016/0304-3959(88)90134-0
  26. Stambaugh JE Jr, Drew J. The combination of ibuprofen and oxycodone/acetaminophen in the management of chronic cancer pain. Clin Pharmacol Ther 1988; 44: 665-9. https://doi.org/10.1038/clpt.1988.209
  27. Sacchetti G, Camera P, Rossi AP, Martoni A, Bruni G, Pannuti F. Injectable ketoprofen vs. acetylsalicylic acid for the relief of severe cancer pain: a double-blind, crossover trial. Drug Intell Clin Pharm 1984; 18: 403-6. https://doi.org/10.1177/106002808401800510
  28. McNicol E, Strassels SA, Goudas L, Lau J, Carr DB. NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database Syst Rev 2005; (1): CD005180.
  29. Sheng H, Shao J, Kirkland SC, Isakson P, Coffey RJ, Morrow J, et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997; 99: 2254-9. https://doi.org/10.1172/JCI119400
  30. Sabino MA, Ghilardi JR, Jongen JL, Keyser CP, Luger NM, Mach DB, et al. Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2. Cancer Res 2002; 62: 7343-9.
  31. Isono M, Suzuki T, Hosono K, Hayashi I, Sakagami H, Uematsu S, et al. Microsomal prostaglandin E synthase-1 enhances bone cancer growth and bone cancer-related pain behaviors in mice. Life Sci 2011; 88: 693-700. https://doi.org/10.1016/j.lfs.2011.02.008
  32. Bruera E, Roca E, Cedaro L, Carraro S, Chacon R. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 1985; 69: 751-4.
  33. Cain DM, Wacnik PW, Turner M, Wendelschafer-Crabb G, Kennedy WR, Wilcox GL, et al. Functional interactions between tumor and peripheral nerve: changes in excitability and morphology of primary afferent fibers in a murine model of cancer pain. J Neurosci 2001; 21: 9367-76.
  34. Peters CM, Ghilardi JR, Keyser CP, Kubota K, Lindsay TH, Luger NM, et al. Tumor-induced injury of primary afferent sensory nerve fibers in bone cancer pain. Exp Neurol 2005; 193: 85-100. https://doi.org/10.1016/j.expneurol.2004.11.028
  35. Halvorson KG, Sevcik MA, Ghilardi JR, Rosol TJ, Mantyh PW. Similarities and differences in tumor growth, skeletal remodeling and pain in an osteolytic and osteoblastic model of bone cancer. Clin J Pain 2006; 22: 587-600. https://doi.org/10.1097/01.ajp.0000210902.67849.e6
  36. Jimenez-Andrade JM, Mantyh P. Cancer pain: from the development of mouse models to human clinical trials. In: Translational pain research: from mouse to man. Edited by Kruger L, Light AR. Boca Raton (FL), CRC Press. 2010, pp 1-22.
  37. Donovan-Rodriguez T, Dickenson AH, Urch CE. Gabapentin normalizes spinal neuronal responses that correlate with behavior in a rat model of cancer-induced bone pain. Anesthesiology 2005; 102: 132-40. https://doi.org/10.1097/00000542-200501000-00022
  38. Caraceni A, Zecca E, Bonezzi C, Arcuri E, Yaya Tur R, Maltoni M, et al. Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol 2004; 22: 2909-17. https://doi.org/10.1200/JCO.2004.08.141
  39. Caraceni A, Zecca E, Martini C, Pigni A, Bracchi P. Gabapentin for breakthrough pain due to bone metastases. Palliat Med 2008; 22: 392-3. https://doi.org/10.1177/0269216308089304
  40. Kato A, Minami K, Ito H, Tomii T, Matsumoto M, Orita S, et al. Oxycodone-induced analgesic effects in a bone cancer pain model in mice. Oncology 2008; 74 Suppl 1: 55-60. https://doi.org/10.1159/000143220
  41. Bailey F, Farley A. Oral opioid drugs. In: Cancer-related breakthrough pain. Edited by Davies A. Oxford, Oxford University Press. 2006, pp 43-55.
  42. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999; 81: 129-34. https://doi.org/10.1016/S0304-3959(99)00006-8
  43. Costa L, Major PP. Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol 2009; 6: 163-74. https://doi.org/10.1038/ncponc1323
  44. Mönkkönen H, Auriola S, Lehenkari P, Kellinsalmi M, Hassinen IE, Vepsäläinen J, et al. A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br J Pharmacol 2006; 147: 437-45. https://doi.org/10.1038/sj.bjp.0706628
  45. Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC, et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002; 20: 3719-36. https://doi.org/10.1200/JCO.2002.06.037
  46. Pistevou-Gombaki K, Eleftheriadis N, Sofroniadis I, Makris P, Kouloulias V. Palliative treatment of painful bone metastases from non-Hodgkin lymphoma with disodium pamidronate. J Exp Clin Cancer Res 2002; 21: 429-32.
  47. Santini D, Fratto ME, Vincenzi B, Galluzzo S, Tonini G. Zoledronic acid in the management of metastatic bone disease. Expert Opin Biol Ther 2006; 6: 1333-48. https://doi.org/10.1517/14712598.6.12.1333
  48. Amir E, Whyne C, Freedman OC, Fralick M, Kumar R, Hardisty M, et al. Radiological changes following second-line zoledronic acid treatment in breast cancer patients with bone metastases. Clin Exp Metastasis 2009; 26: 479-84. https://doi.org/10.1007/s10585-009-9247-x
  49. Hiraga T, Williams PJ, Ueda A, Tamura D, Yoneda T. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 2004; 10: 4559-67. https://doi.org/10.1158/1078-0432.CCR-03-0325
  50. Furlow B. Zoledronic acid palliation in bone-metastatic breast cancer. Lancet Oncol 2006; 7: 894.
  51. Fulfaro F, Leto G, Badalamenti G, Arcara C, Cicero G, Valerio MR, et al. The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers. J Chemother 2005; 17: 555-9. https://doi.org/10.1179/joc.2005.17.5.555
  52. Rachner TD, Singh SK, Schoppet M, Benad P, Bornhäuser M, Ellenrieder V, et al. Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells. Cancer Lett 2010; 287: 109-16. https://doi.org/10.1016/j.canlet.2009.06.003
  53. Woodward JK, Neville-Webbe HL, Coleman RE, Holen I. Combined effects of zoledronic acid and doxorubicin on breast cancer cell invasion in vitro. Anticancer Drugs 2005; 16: 845-54. https://doi.org/10.1097/01.cad.0000175582.01446.6f
  54. Santini D, Vincenzi B, Galluzzo S, Battistoni F, Rocci L, Venditti O, et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 2007; 13: 4482-6. https://doi.org/10.1158/1078-0432.CCR-07-0551
  55. Vincenzi B, Santini D, Dicuonzo G, Battistoni F, Gavasci M, La Cesa A, et al. Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res 2005; 25: 144-51. https://doi.org/10.1089/jir.2005.25.144
  56. Tong D, Gillick L, Hendrickson FR. The palliation of symptomatic osseous metastases: final results of the study by the Radiation Therapy Oncology Group. Cancer 1982; 50: 893-9. https://doi.org/10.1002/1097-0142(19820901)50:5<893::AID-CNCR2820500515>3.0.CO;2-Y
  57. Arcangeli G, Micheli A, Arcangeli G, Giannarelli D, La Pasta O, Tollis A, et al. The responsiveness of bone metastases to radiotherapy: the effect of site, histology and radiation dose on pain relief. Radiother Oncol 1989; 14: 95-101. https://doi.org/10.1016/0167-8140(89)90053-4
  58. Dennis K, Wong K, Zhang L, Culleton S, Nguyen J, Holden L, et al. Palliative radiotherapy for bone metastases in the last 3 months of life: worthwhile or futile? Clin Oncol (R Coll Radiol) 2011; 23: 709-15. https://doi.org/10.1016/j.clon.2011.05.004
  59. Poulter CA, Cosmatos D, Rubin P, Urtasun R, Cooper JS, Kuske RR, et al. A report of RTOG 8206: a phase III study of whether the addition of single dose hemibody irradiation to standard fractionated local field irradiation is more effective than local field irradiation alone in the treatment of symptomatic osseous metastases. Int J Radiat Oncol Biol Phys 1992; 23: 207-14. https://doi.org/10.1016/0360-3016(92)90563-W
  60. Jeremic B. Single fraction external beam radiation therapy in the treatment of localized metastatic bone pain. A review. J Pain Symptom Manage 2001; 22: 1048-58. https://doi.org/10.1016/S0885-3924(01)00359-1
  61. Wu JS, Wong R, Johnston M, Bezjak A, Whelan T; Cancer Care Ontario Practice Guidelines Initiative Supportive Care Group. Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys 2003; 55: 594-605. https://doi.org/10.1016/S0360-3016(02)04147-0
  62. Sze WM, Shelley MD, Held I, Wilt TJ, Mason MD. Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy--a systematic review of randomised trials. Clin Oncol (R Coll Radiol) 2003; 15: 345-52. https://doi.org/10.1016/S0936-6555(03)00113-4
  63. Chow E, Harris K, Fan G, Tsao M, Sze WM. Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol 2007; 25: 1423-36. https://doi.org/10.1200/JCO.2006.09.5281
  64. Rades D, Schild SE, Abrahm JL. Treatment of painful bone metastases. Nat Rev Clin Oncol 2010; 7: 220-9. https://doi.org/10.1038/nrclinonc.2010.17
  65. Nomiya T, Teruyama K, Wada H, Nemoto K. Time course of pain relief in patients treated with radiotherapy for cancer pain: a prospective study. Clin J Pain 2010; 26: 38-42. https://doi.org/10.1097/AJP.0b013e3181b0c82c
  66. Huisman M, van den Bosch MA, Wijlemans JW, van Vulpen M, van der Linden YM, Verkooijen HM. Effectiveness of reirradiation for painful bone metastases: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys 2012; 84: 8-14. https://doi.org/10.1016/j.ijrobp.2011.10.080
  67. Smith H, Navani A, Fishman SM. Radiopharmaceuticals for palliation of painful osseous metastases. Am J Hosp Palliat Care 2004; 21: 303-13. https://doi.org/10.1177/104990910402100415
  68. Roqué I Figuls M, Martinez-Zapata MJ, Scott-Brown M, Alonso-Coello P. Radioisotopes for metastatic bone pain. Cochrane Database Syst Rev 2011; (7): CD003347.
  69. Paes FM, Serafini AN. Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain. Semin Nucl Med 2010; 40: 89-104. https://doi.org/10.1053/j.semnuclmed.2009.10.003
  70. Robinson RG, Preston DF, Spicer JA, Baxter KG. Radionuclide therapy of intractable bone pain: emphasis on strontium-89. Semin Nucl Med 1992; 22: 28-32. https://doi.org/10.1016/S0001-2998(05)80154-0
  71. Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol 2005; 6: 392-400. https://doi.org/10.1016/S1470-2045(05)70206-0
  72. Samarium-153 lexidronam for painful bone metastases. Med Lett Drugs Ther 1997; 39: 83-4.
  73. Alberts AS, Smit BJ, Louw WK, van Rensburg AJ, van Beek A, Kritzinger V, et al. Dose response relationship and multiple dose efficacy and toxicity of samarium-153-EDTMP in metastatic cancer to bone. Radiother Oncol 1997; 43: 175-9. https://doi.org/10.1016/S0167-8140(97)01912-9
  74. Sartor O, Reid RH, Bushnell DL, Quick DP, Ell PJ. Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. Cancer 2007; 109: 637-43. https://doi.org/10.1002/cncr.22431
  75. Nazario J, Hernandez J, Tam AL. Thermal ablation of painful bone metastases. Tech Vasc Interv Radiol 2011; 14: 150-9. https://doi.org/10.1053/j.tvir.2011.02.007
  76. Callstrom MR, Charboneau JW. Image-guided palliation of painful metastases using percutaneous ablation. Tech Vasc Interv Radiol 2007; 10: 120-31. https://doi.org/10.1053/j.tvir.2007.09.003
  77. Di Staso M, Zugaro L, Gravina GL, Bonfili P, Marampon F, Di Nicola L, et al. A feasibility study of percutaneous radiofrequency ablation followed by radiotherapy in the management of painful osteolytic bone metastases. Eur Radiol 2011; 21: 2004-10. https://doi.org/10.1007/s00330-011-2133-3
  78. Dupuy DE, Hong R, Oliver B, Goldberg SN. Radiofrequency ablation of spinal tumors: temperature distribution in the spinal canal. AJR Am J Roentgenol 2000; 175: 1263-6. https://doi.org/10.2214/ajr.175.5.1751263
  79. Tancioni F, Lorenzetti MA, Navarria P, Pessina F, Draghi R, Pedrazzoli P, et al. Percutaneous vertebral augmentation in metastatic disease: state of the art. J Support Oncol 2011; 9: 4-10. https://doi.org/10.1016/j.suponc.2011.01.001
  80. Peh WC, Gilula LA. Percutaneous vertebroplasty: indications, contraindications, and technique. Br J Radiol 2003; 76: 69-75. https://doi.org/10.1259/bjr/10254271
  81. Lee B, Franklin I, Lewis JS, Coombes RC, Leonard R, Gishen P, et al. The efficacy of percutaneous vertebroplasty for vertebral metastases associated with solid malignancies. Eur J Cancer 2009; 45: 1597-602. https://doi.org/10.1016/j.ejca.2009.01.021
  82. Saliou G, Kocheida el M, Lehmann P, Depriester C, Paradot G, Le Gars D, et al. Percutaneous vertebroplasty for pain management in malignant fractures of the spine with epidural involvement. Radiology 2010; 254: 882-90. https://doi.org/10.1148/radiol.09081698
  83. Kassamali RH, Ganeshan A, Hoey ET, Crowe PM, Douis H, Henderson J. Pain management in spinal metastases: the role of percutaneous vertebral augmentation. Ann Oncol 2011; 22: 782-6. https://doi.org/10.1093/annonc/mdq605
  84. Qian Z, Sun Z, Yang H, Gu Y, Chen K, Wu G. Kyphoplasty for the treatment of malignant vertebral compression fractures caused by metastases. J Clin Neurosci 2011; 18: 763-7. https://doi.org/10.1016/j.jocn.2010.09.021
  85. Smith TJ, Staats PS, Deer T, Stearns LJ, Rauck RL, Boortz-Marx RL, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol 2002; 20: 4040-9. https://doi.org/10.1200/JCO.2002.02.118
  86. Deer T, Krames ES, Hassenbusch SJ, Burton A, Caraway D, Dupen S, et al. Polyanalgesic consensus conference 2007: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation 2007; 10: 300-28. https://doi.org/10.1111/j.1525-1403.2007.00128.x
  87. Deer TR, Smith HS, Burton AW, Pope JE, Doleys DM, Levy RM, et al. Comprehensive consensus based guidelines on intrathecal drug delivery systems in the treatment of pain caused by cancer pain. Pain Physician 2011; 14: E283-312.
  88. Papachristou DJ, Basdra EK, Papavassiliou AG. Bone metastases: molecular mechanisms and novel therapeutic interventions. Med Res Rev 2012; 32: 611-36. https://doi.org/10.1002/med.20224
  89. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999; 402: 304-9. https://doi.org/10.1038/46303
  90. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 1999; 96: 3540-5. https://doi.org/10.1073/pnas.96.7.3540
  91. Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand JP, et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003; 97: 887-92. https://doi.org/10.1002/cncr.11138
  92. Schwarz EM, Ritchlin CT. Clinical development of anti- RANKL therapy. Arthritis Res Ther 2007; 9 Suppl 1: S7.
  93. Kaan TK, Yip PK, Patel S, Davies M, Marchand F, Cockayne DA, et al. Systemic blockade of P2X3 and P2X2/3 receptors attenuates bone cancer pain behaviour in rats. Brain 2010; 133: 2549-64. https://doi.org/10.1093/brain/awq194
  94. Chen J, Wang L, Zhang Y, Yang J. P2Y1 purinoceptor inhibition reduces extracellular signal-regulated protein kinase 1/2 phosphorylation in spinal cord and dorsal root ganglia: implications for cancer-induced bone pain. Acta Biochim Biophys Sin (Shanghai) 2012; 44: 367-72. https://doi.org/10.1093/abbs/gms007
  95. Tomura H, Mogi C, Sato K, Okajima F. Proton-sensing and lysolipid-sensitive G-protein-coupled receptors: a novel type of multi-functional receptors. Cell Signal 2005; 17: 1466-76. https://doi.org/10.1016/j.cellsig.2005.06.002
  96. Huang CW, Tzeng JN, Chen YJ, Tsai WF, Chen CC, Sun WH. Nociceptors of dorsal root ganglion express proton-sensing G-protein-coupled receptors. Mol Cell Neurosci 2007; 36: 195-210. https://doi.org/10.1016/j.mcn.2007.06.010
  97. Chen YJ, Huang CW, Lin CS, Chang WH, Sun WH. Expression and function of proton-sensing G-protein-coupled receptors in inflammatory pain. Mol Pain 2009; 5: 39. https://doi.org/10.1186/1744-8069-5-39
  98. Pérez-Sayáns M, Somoza-Martín JM, Barros-Angueira F, Rey JM, García-García A. V-ATPase inhibitors and implication in cancer treatment. Cancer Treat Rev 2009; 35: 707-13. https://doi.org/10.1016/j.ctrv.2009.08.003
  99. Reeh PW, Steen KH. Tissue acidosis in nociception and pain. Prog Brain Res 1996; 113: 143-51. https://doi.org/10.1016/S0079-6123(08)61085-7
  100. Sin WC, Zhang Y, Zhong W, Adhikarakunnathu S, Powers S, Hoey T, et al. G protein-coupled receptors GPR4 and TDAG8 are oncogenic and overexpressed in human cancers. Oncogene 2004; 23: 6299-303. https://doi.org/10.1038/sj.onc.1207838
  101. Hang LH, Yang JP, Yin W, Wang LN, Guo F, Ji FH, et al. Activation of spinal TDAG8 and its downstream PKA signaling pathway contribute to bone cancer pain in rats. Eur J Neurosci 2012; 36: 2107-17. https://doi.org/10.1111/j.1460-9568.2012.08087.x
  102. Lozano-Ondoua AN, Hanlon KE, Symons-Liguori AM, Largent-Milnes TM, Havelin JJ, Ferland HL 3rd, et al. Disease modification of breast cancer-induced bone remodeling by cannabinoid 2 receptor agonists. J Bone Miner Res 2013; 28: 92-107. https://doi.org/10.1002/jbmr.1732
  103. Hu S, Mao-Ying QL, Wang J, Wang ZF, Mi WL, Wang XW, et al. Lipoxins and aspirin-triggered lipoxin alleviate bone cancer pain in association with suppressing expression of spinal proinflammatory cytokines. J Neuroinflammation 2012; 9: 278. https://doi.org/10.1186/1742-2094-9-278

Cited by

  1. Radiofrequency Thermal Ablation in Painful Myeloma of the Clavicle vol.27, pp.1, 2014, https://doi.org/10.3344/kjp.2014.27.1.72
  2. Tageted bipolar radiofrequency decompression with vertebroplasty for intractable radicular pain due to spinal metastasis: a case report vol.69, pp.4, 2016, https://doi.org/10.4097/kjae.2016.69.4.395
  3. Extraspinal Percutaneous Osteoplasty for the Treatment of Painful Bony Metastasis vol.33, pp.8, 2018, https://doi.org/10.3346/jkms.2018.33.e61
  4. Efficacy of Cryoablation to Control Cancer Pain: A Systematic Review pp.15307085, 2018, https://doi.org/10.1111/papr.12707
  5. Predictors of analgesic efficacy of neurolytic celiac plexus block in patients with unresectable pancreatic cancer: the importance of timing vol.26, pp.6, 2018, https://doi.org/10.1007/s00520-018-4043-2
  6. Considerations for Exercise Prescription in Patients With Bone Metastases: A Comprehensive Narrative Review vol.10, pp.8, 2018, https://doi.org/10.1016/j.pmrj.2018.02.006
  7. Tumor Necrosis Factor-α Produced by Osteoclasts Might Induce Intractable Pain in a Rat Spinal Metastasis Model of Breast Cancer vol.3, pp.3, 2013, https://doi.org/10.22603/ssrr.2018-0106
  8. Randomized controlled trials between dorsal root ganglion thermal radiofrequency, pulsed radiofrequency and steroids for the management of intractable metastatic back pain in thoracic vertebral body vol.15, pp.3, 2021, https://doi.org/10.1177/2049463720942538